Indoco Remedies Limited Stock Price Today (NSE: INDOCO)
Fundamental Score
Indoco Remedies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Indoco Remedies Limited share price today is ₹254.00, up +5.22% on NSE/BSE as of 16 September 2026. Indoco Remedies Limited (INDOCO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.34K (Cr). The 52-week high for INDOCO share price is ₹325.00 and the 52-week low is ₹162.19. At a P/E ratio of 793.75x, INDOCO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of -9.70% and a debt-to-equity ratio of 1.10.
Indoco Remedies Limited Share Price Chart — NSE/BSE Historical Performance
Indoco Remedies Limited share price chart: 14.83% return over the past month. 52-week high ₹325.00, 52-week low ₹162.19.
Indoco Remedies Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹241.39 | ₹258.00 | ₹235.00 | ₹254.00 | 6.44L (Cr) | |
| ₹263.02 | ₹265.92 | ₹238.50 | ₹241.39 | 3.55L (Cr) | |
| ₹260.00 | ₹276.98 | ₹251.50 | ₹263.02 | 50.02L (Cr) | |
| ₹234.94 | ₹269.90 | ₹229.00 | ₹254.25 | 60.15L (Cr) | |
| ₹242.00 | ₹246.29 | ₹229.50 | ₹231.18 | 5.70L (Cr) | |
| ₹250.73 | ₹256.88 | ₹243.00 | ₹244.25 | 1.76L (Cr) | |
| ₹249.30 | ₹257.24 | ₹248.06 | ₹250.70 | 3.15L (Cr) | |
| ₹272.95 | ₹274.70 | ₹260.59 | ₹262.51 | 3.69L (Cr) | |
| ₹273.36 | ₹283.50 | ₹266.38 | ₹272.56 | 14.90L (Cr) | |
| ₹242.00 | ₹287.80 | ₹241.34 | ₹273.77 | 192.25L (Cr) |
Indoco Remedies Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹243.34 | ₹287.80 | ₹229.00 | ₹254.00 | +4.38% | |
| ₹222.78 | ₹253.70 | ₹214.06 | ₹243.34 | +9.23% | |
| ₹237.00 | ₹268.00 | ₹216.03 | ₹219.49 | -7.39% | |
| ₹210.00 | ₹261.71 | ₹198.00 | ₹239.22 | +13.91% | |
| ₹211.10 | ₹270.00 | ₹191.00 | ₹209.66 | -0.68% | |
| ₹169.90 | ₹227.85 | ₹167.61 | ₹209.49 | +23.30% | |
| ₹195.00 | ₹206.09 | ₹162.19 | ₹164.00 | -15.90% | |
| ₹210.00 | ₹246.70 | ₹195.00 | ₹202.28 | -3.68% | |
| ₹235.60 | ₹235.60 | ₹202.96 | ₹217.51 | -7.68% | |
| ₹257.70 | ₹262.50 | ₹222.00 | ₹234.60 | -8.96% | |
| ₹282.00 | ₹288.00 | ₹250.10 | ₹256.15 | -9.17% | |
| ₹287.55 | ₹317.35 | ₹270.70 | ₹279.15 | -2.92% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Indoco Remedies Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indoco Remedies Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDOCO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (58.90%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-9.70%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.00%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 793.75x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-281.59%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.10)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (0.13x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-105.13 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Indoco Remedies Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Indoco Remedies Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Indoco Remedies LimitedIndoco Remedies...Selected✓ INDOCO • 532612 | 26.9/100 | ₹254.00₹254 | ₹2344.42₹2344.42 | 793.75Average 793.8 Average | -9.70%Poor -9.70% Poor | 1.00%Poor 1.00% Poor | 1.10Average 1.1 Average | — — | 8.25%Good 8.25% Good | 0.08% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.41₹95007.41 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Indoco Remedies Limited PE Ratio History
Historical price-to-earnings ratio for INDOCO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹10.51 | ₹332.20 | 31.6x |
| FY 2023 | ₹15.42 | ₹395.20 | 25.6x |
| FY 2022 | ₹16.80 | ₹406.65 | 24.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Indoco Remedies Limited Dividend History
Annual cash dividends paid by INDOCO — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹13.90 Cr |
| FY 2024 | ₹20.71 Cr |
| FY 2023 | ₹20.72 Cr |
| FY 2022 | ₹13.79 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Indoco Remedies Limited Quarterly Performance
Latest quarterly metrics for INDOCO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
6.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-281.59%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.25%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Indoco Remedies Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDOCO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Indoco Remedies Limited Financial Statements
Annual income statement, balance sheet and cash flow for Indoco Remedies Limited (INDOCO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Indoco Remedies Limited
About INDOCO (Indoco Remedies Limited)
Indoco Remedies Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of finished pharmaceuti...cal dosages. With a strong emphasis on innovation and quality, Indoco has built a reputation for delivering effective and affordable healthcare solutions across diverse therapeutic segments. Their expansive product portfolio caters to both domestic and international markets, solidifying their position as a trusted partner in the global pharmaceutical landscape. Driven by a commitment to scientific excellence and ethical business practices, Indoco continuously strives to improve patient outcomes and contribute to the advancement of healthcare worldwide, all while maintaining rigorous adherence to international regulatory standards. The company's therapeutic focus is exceptionally broad, encompassing critical areas such as pain management, diabetes care, cardiovascular health, and women's health. Indoco's product offerings include a diverse range of formulations, including tablets, capsules, injectables, and topical preparations, each developed with a meticulous attention to detail and adherence to strict quality control measures. By leveraging cutting-edge technology and a highly skilled workforce, Indoco remains at the forefront of pharmaceutical innovation, constantly seeking to develop novel and improved therapies that address unmet medical needs. The company's strategic partnerships and collaborations further enhance its capabilities and expand its reach, ensuring that its products are accessible to patients across the globe. Indoco's commitment to sustainable growth is evident in its continuous investments in research and development, manufacturing infrastructure, and human capital. The company operates state-of-the-art manufacturing facilities that are compliant with international regulatory standards, ensuring the consistent production of high-quality pharmaceutical products. Furthermore, Indoco places a strong emphasis on environmental sustainability, implementing eco-friendly practices throughout its operations. By combining its dedication to scientific advancement with a responsible and ethical approach to business, Indoco Remedies Ltd is poised to continue its trajectory of growth and contribute meaningfully to the health and well-being of communities worldwide.
Company Details
Key Leadership
INDOCO Share Price: Frequently Asked Questions
What is the current share price of Indoco Remedies Limited?
Indoco Remedies Limited (INDOCO) trades at ₹254.00 on NSE and BSE. Market cap ₹2.34K (Cr). Educational data only.
What is the P/E ratio of Indoco Remedies Limited?
Indoco Remedies Limited has a P/E of 793.75x vs industry average 34.89x.
What is the Bull Run score for Indoco Remedies Limited?
Indoco Remedies Limited has a Bull Run score of 26.9/100 based on 25+ financial parameters.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of Indoco Remedies Limited?
Indoco Remedies Limited has ROE of -9.70%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Indoco Remedies Limited?
Indoco Remedies Limited has debt-to-equity of 1.10.
Is Indoco Remedies Limited a good investment?
Bull Run gives Indoco Remedies Limited a score of 26.9/100. This is not investment advice — consult a SEBI-registered advisor.